REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT01803828

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01803828
Other papers using this trial's data
  • Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial Science translational medicine, 2022-06-15 DOI, PubMed 35704597

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01803828. Randomized; double masking; primary purpose treatment. Start 2014-05 (actual); primary completion 2019-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs
Acronym
RECOGITO
Condition
Diabetic Cardiomyopathy
Condition
Diabetes Mellitus Type 2
Intervention (Drug)
Tadalafil
Intervention (Drug)
Placebo
Lead sponsor
University of Roma La Sapienza (class: other)

Record details

Record id
cardio:ct-nct01803828
Content hash
65f75cd593ef411dde58314777863172eecdd72c0acfc585eeeca79f8cbe74f7